Time to meaningful clinical response in reduction of itch in atopic dermatitis

References

• Silverberg J. Atopic dermatitis in adults. Med Clin North Am. 2020;104(1):157–176.
   PubMed Web of Science ®Google Scholar
• Silverberg J, Gelfand J, Margolis D, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–347.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–769.
   PubMed Web of Science ®Google Scholar
• Nwachukwu B, Chang B, Adjei J, et al. Time required to achieve minimal clinically important difference and substantial clinical benefit after arthroscopic treatment of femoroacetabular impingement. Am J Sports Med. 2018;46(11):2601–2606.
   PubMed Web of Science ®Google Scholar
• Rohatgi A. WebPlotDigitizer version 4.2. 2019. Available from https://automeris.io/WebPlotDigitizer.
   Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year randomized, double-blinded, placebo-controlled phase 3 trial. Lancet. 2017;389(10086):2287–2303.
   PubMed Web of Science ®Google Scholar
• Simpson E, Gadkari A, Worm M, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol. 2016;75(3):506–515.
   PubMed Web of Science ®Google Scholar
• Simpson E, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Blauvelt A, Eichenfield L, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411.
   PubMed Web of Science ®Google Scholar
• Silverberg J, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173–182.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Howell M, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135–141.
   PubMed Web of Science ®Google Scholar
• Simpson E, Parnes J, She D, et al. Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J Am Acad of Dermatol. 2019;80(4):1013–1021.
   PubMed Web of Science ®Google Scholar
• Gooderham M, Forman S, Bissonnette R, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis. JAMA Dermatol. 2019;155(12):1371–1379.
   PubMed Web of Science ®Google Scholar
• Simpson E, Lacour J, Spelman L, et al. Efficacy and safety of baricitinib in moderate-to-severe atopic dermatitis: results of two phase 3 monotherapy randomized, double-blind, placebo-controlled 16-week trials (BREEZE-AD1 and BREEZE-AD2). Presented at: 24th World Congress of Dermatology (WCD); 2019 June 10–15; Milan, Italy.
   Google Scholar
• Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Silverberg J, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913–921.
   PubMed Web of Science ®Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in moderate to severe atopic dermatitis: results of a phase 3 randomized, double-blind, placebo-controlled 16-week trial (BREEZE-AD7). Presented at: 24th World Congress of Dermatology (WCD); 2019 June 10–15; Milan, Italy.
   Google Scholar
• Reich K, Guttman-Yassky E, Beck L, et al. Early response to upadacitinib in moderate to-severe atopic dermatitis; results from a phase 2b randomized, placebo-controlled trial. Presented at European Academy of Allergy and Clinical Immunology (EAACI); 2019 June 1–5; Lisbon, Portugal.
   Google Scholar
• Guttman-Yassky E, Thaci D, Pangan A, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877–884.
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Muller A, Lauerma A, et al. IL-31: A new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–417.
   PubMed Web of Science ®Google Scholar
• Oetjen L, Mack M, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217–228.
   PubMed Web of Science ®Google Scholar
• Grinich E, Schmitt J, Küster D, et al. Standardized reporting of the eczema area and severity index (EASI) and the patient-oriented eczema measure (POEM): a recommendation by the harmonising outcome measures for eczema (HOME) initiative. Br J Dermatol. 2018;179(2):540–541.
   PubMed Web of Science ®Google Scholar
• Schram M, Spuls P, Leeflang M, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106.
   PubMed Web of Science ®Google Scholar